New insights into binding of natural chalcones to Bcl-2, Bcl-xL and Mcl-1 anti-apoptotic proteins

被引:0
作者
cirin, Dejan [1 ]
Krstonosic, Veljko [1 ]
机构
[1] Univ Novi Sad, Fac Med, Dept Pharm, Hajduk Veljkova 3, Novi Sad 21000, Serbia
关键词
natural chalcones; Bcl-2; proteins; BH3-binding groove; docking study; MM-GBSA; molecular dynamics; MULTIDRUG-RESISTANCE; ACCURATE PREDICTION; FLAVOKAWAIN B; CANCER CELLS; INHIBITORS; DYNAMICS; DOCKING; NAVITOCLAX; ANTITUMOR; LEUKEMIA;
D O I
10.1016/j.molstruc.2021.130700
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Knowledge about mechanisms responsible for induction of tumor cell apoptosis is important for the development of anticancer drugs. Mounting evidence suggests that the inhibition of anti-apoptotic proteins of Bcl-2 family is important part of antitumor activity of natural chalcones. In order to gain insights into their binding affinity and binding mechanism, the MM-GBSA binding energies were determined for 63 natural chalcones to Bcl-2, Bcl-xL and Mcl-1, by employing multiple crystal structures of each antiapoptotic protein. It was noticed that the chalcones have high affinity to the BH3-binding groove. The driving forces behind the binding and the anchor points on the proteins were determined for the top ranked chalcones, whereas the 30 0-ns Molecular Dynamics (MD) simulations provided more insights into the binding in the most stable complexes. The importance of ring A, ring B and the side chains of the chalcones for the interactions with the hydrophobic cavities of anti-apoptotic proteins was noticed. Although the natural compounds showed mainly favorable pharmacokinetic properties, some limitations in binding to the proteins, compared to the synthetic ligands, were noticed. This pointed out towards possible future directions of chemical modifications of the most potent natural compounds. It is envisioned that the results of this study could be useful for the selection of lead antitumor natural compounds as well as for the design of new synthetic BH3-mimetics. (c) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页数:15
相关论文
共 56 条
  • [31] The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
    Lieber, Justus
    Eicher, Carmen
    Wenz, Julia
    Kirchner, Bettina
    Warmann, Steven W.
    Fuchs, Joerg
    Armeanu-Ebinger, Sorin
    [J]. BMC CANCER, 2011, 11
  • [32] Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring
    Lyne, Paul D.
    Lamb, Michelle L.
    Saeh, Jamal C.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (16) : 4805 - 4808
  • [33] CONSTANT-PRESSURE MOLECULAR-DYNAMICS ALGORITHMS
    MARTYNA, GJ
    TOBIAS, DJ
    KLEIN, ML
    [J]. JOURNAL OF CHEMICAL PHYSICS, 1994, 101 (05) : 4177 - 4189
  • [34] Homology Modeling and Docking Evaluation of Aminergic G Protein-Coupled Receptors
    McRobb, Fiona M.
    Capuano, Ben
    Crosby, Ian T.
    Chalmers, David K.
    Yuriev, Elizabeth
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2010, 50 (04) : 626 - 637
  • [35] BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
    Merino, Delphine
    Kelly, Gemma L.
    Lessene, Guillaume
    Wei, Andrew H.
    Roberts, Andrew W.
    Strasser, Andreas
    [J]. CANCER CELL, 2018, 34 (06) : 879 - 891
  • [36] Broad targeting of resistance to apoptosis in cancer
    Mohammad, Ramzi M.
    Muqbil, Irfana
    Lowe, Leroy
    Yedjou, Clement
    Hsu, Hsue-Yin
    Lin, Liang-Tzung
    Siegelin, Markus David
    Fimognari, Carmela
    Kumar, Nagi B.
    Dou, Q. Ping
    Yang, Huanjie
    Samadi, Abbas K.
    Russo, Gian Luigi
    Spagnuolo, Carmela
    Ray, Swapan K.
    Chakrabarti, Mrinmay
    Morre, James D.
    Coley, Helen M.
    Honoki, Kanya
    Fujii, Hiromasa
    Georgakilas, Alexandros G.
    Amedei, Amedeo
    Niccolai, Elena
    Amin, Amr
    Ashraf, S. Salman
    Helferich, William G.
    Yang, Xujuan
    Boosani, Chandra S.
    Guha, Gunjan
    Bhakta, Dipita
    Ciriolo, Maria Rosa
    Aquilano, Katia
    Chen, Sophie
    Mohammed, Sulma I.
    Keith, W. Nicol
    Bilsland, Alan
    Halicka, Dorota
    Nowsheen, Somaira
    Azmi, Asfar S.
    [J]. SEMINARS IN CANCER BIOLOGY, 2015, 35 : S78 - S103
  • [37] Development of Mcl-1 inhibitors for cancer therapy
    Negi, Arvind
    Murphy, Paul, V
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 210
  • [38] A UNIFIED FORMULATION OF THE CONSTANT TEMPERATURE MOLECULAR-DYNAMICS METHODS
    NOSE, S
    [J]. JOURNAL OF CHEMICAL PHYSICS, 1984, 81 (01) : 511 - 519
  • [39] An inhibitor of Bcl-2 family proteins induces regression of solid tumours
    Oltersdorf, T
    Elmore, SW
    Shoemaker, AR
    Armstrong, RC
    Augeri, DJ
    Belli, BA
    Bruncko, M
    Deckwerth, TL
    Dinges, J
    Hajduk, PJ
    Joseph, MK
    Kitada, S
    Korsmeyer, SJ
    Kunzer, AR
    Letai, A
    Li, C
    Mitten, MJ
    Nettesheim, DG
    Ng, S
    Nimmer, PM
    O'Connor, JM
    Oleksijew, A
    Petros, AM
    Reed, JC
    Shen, W
    Tahir, SK
    Thompson, CB
    Tomaselli, KJ
    Wang, BL
    Wendt, MD
    Zhang, HC
    Fesik, SW
    Rosenberg, SH
    [J]. NATURE, 2005, 435 (7042) : 677 - 681
  • [40] Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods
    Pelz, Nicholas F.
    Bian, Zhiguo
    Zhao, Bin
    Shaw, Subrata
    Tarr, James C.
    Belmar, Johannes
    Gregg, Claire
    Camper, DeMarco V.
    Goodwin, Craig M.
    Arnold, Allison L.
    Sensintaffar, John L.
    Friberg, Anders
    Rossanese, Olivia W.
    Lee, Taekyu
    Olejniczak, Edward T.
    Fesik, Stephen W.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (05) : 2054 - 2066